373 related articles for article (PubMed ID: 33992698)
1. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
[TBL] [Abstract][Full Text] [Related]
2. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
3. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
4. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
[TBL] [Abstract][Full Text] [Related]
5. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y; Saito Y; Takasugi A; Toshimitsu K; Yamada S; Muramatsu T; Kimura M; Sugiyama K; Suzuki H; Arai E; Ojima H; Kanai Y; Saito H
Cancer Sci; 2014 Oct; 105(10):1254-60. PubMed ID: 25117675
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
10. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
11. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.
Weinmann A; Alt Y; Koch S; Nelles C; Düber C; Lang H; Otto G; Zimmermann T; Marquardt JU; Galle PR; Wörns MA; Schattenberg JM
BMC Cancer; 2015 Apr; 15():210. PubMed ID: 25884354
[TBL] [Abstract][Full Text] [Related]
12. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis.
Billeter AT; Müller PC; Albrecht T; Roessler S; Löffler M; Lemekhova A; Mehrabi A; Müller-Stich BP; Hoffmann K
J Gastrointest Surg; 2021 May; 25(5):1193-1202. PubMed ID: 32378092
[TBL] [Abstract][Full Text] [Related]
13. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
14. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
16. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling.
Liang JQ; Teoh N; Xu L; Pok S; Li X; Chu ESH; Chiu J; Dong L; Arfianti E; Haigh WG; Yeh MM; Ioannou GN; Sung JJY; Farrell G; Yu J
Nat Commun; 2018 Oct; 9(1):4490. PubMed ID: 30367044
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.
Haldar D; Kern B; Hodson J; Armstrong MJ; Adam R; Berlakovich G; Fritz J; Feurstein B; Popp W; Karam V; Muiesan P; O'Grady J; Jamieson N; Wigmore SJ; Pirenne J; Malek-Hosseini SA; Hidalgo E; Tokat Y; Paul A; Pratschke J; Bartels M; Trunecka P; Settmacher U; Pinzani M; Duvoux C; Newsome PN; Schneeberger S;
J Hepatol; 2019 Aug; 71(2):313-322. PubMed ID: 31071367
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
20. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.
Amaddeo G; Cao Q; Ladeiro Y; Imbeaud S; Nault JC; Jaoui D; Gaston Mathe Y; Laurent C; Laurent A; Bioulac-Sage P; Calderaro J; Zucman-Rossi J
Gut; 2015 May; 64(5):820-9. PubMed ID: 25021421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]